- Home
- GUG vs DRUG Comparison
GUG vs DRUG Comparison
Compare GUG & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- DRUG
- Stock Information
- Founded
- GUG 2021
- DRUG 2019
- Country
- GUG United States
- DRUG United States
- Employees
- GUG N/A
- DRUG N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- DRUG Pharmaceuticals and Biotechnology
- Sector
- GUG Finance
- DRUG Health Care
- Exchange
- GUG Nasdaq
- DRUG Nasdaq
- Market Cap
- GUG 524.4M
- DRUG 484.7M
- IPO Year
- GUG N/A
- DRUG N/A
- Fundamental
- Price
- GUG $15.78
- DRUG $61.55
- Analyst Decision
- GUG
- DRUG Strong Buy
- Analyst Count
- GUG 0
- DRUG 9
- Target Price
- GUG N/A
- DRUG $81.67
- AVG Volume (30 Days)
- GUG 108.9K
- DRUG 121.3K
- Earning Date
- GUG 01-01-0001
- DRUG 08-11-2025
- Dividend Yield
- GUG 9.67%
- DRUG N/A
- EPS Growth
- GUG N/A
- DRUG N/A
- EPS
- GUG N/A
- DRUG N/A
- Revenue
- GUG N/A
- DRUG N/A
- Revenue This Year
- GUG N/A
- DRUG N/A
- Revenue Next Year
- GUG N/A
- DRUG N/A
- P/E Ratio
- GUG N/A
- DRUG N/A
- Revenue Growth
- GUG N/A
- DRUG N/A
- 52 Week Low
- GUG $12.71
- DRUG $23.18
- 52 Week High
- GUG $15.06
- DRUG $70.23
- Technical
- Relative Strength Index (RSI)
- GUG 48.94
- DRUG 55.12
- Support Level
- GUG $15.42
- DRUG $59.85
- Resistance Level
- GUG $15.83
- DRUG $69.70
- Average True Range (ATR)
- GUG 0.27
- DRUG 6.41
- MACD
- GUG -0.02
- DRUG -0.62
- Stochastic Oscillator
- GUG 41.48
- DRUG 60.30
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.